(+/-)-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-methoxy-2,3,6,7-tetrahydro-[1,4]diazepine-1-carboxylic acid ethyl ester | 1174763-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (+/-)-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-methoxy-2,3,6,7-tetrahydro-[1,4]diazepine-1-carboxylic acid ethyl ester
• 英文别名: ethyl 6-(1,3-dioxoisoindol-2-yl)-7-methoxy-2,3,5,6-tetrahydro-1,4-diazepine-4-carboxylate
• CAS: 1174763-99-5
• 化学式: C₁₇H₁₉N₃O₅
• 分子量: 345.355
• InChiKey: BZUICZTWIBFLHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  88.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (+/-)-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-methoxy-2,3,6,7-tetrahydro-[1,4]diazepine-1-carboxylic acid ethyl ester 在 氯化铵 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以80%的产率得到(+/-)-5-amino-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-2,3,6,7-tetrahydro-[1,4]diazepine-1-carboxylic acid ethyl ester hydrochloride
  参考文献：
  名称：

  Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta

  摘要：

  公式（I）表示的嘧啶酮衍生物或其盐，或其溶剂或水合物：其中：Y代表两个氢原子，硫原子，氧原子或C1-2烷基和一个氢原子；Z代表键，氧原子，氮原子，被氢原子或C1-3烷基，硫原子，亚甲基基团替代的一个或两个基团，选自C1-6烷基，羟基，C1-6烷氧基，C1-2全氟烷基或氨基；R1代表2,3或4-吡啶环或2,4或5-嘧啶环，环可选择地被C1-6烷基，C1-6烷氧基或卤原子替代；R2代表氢原子，C1-6烷基或卤原子；R3代表苯环或萘环；环可选择地被替代R4代表氢原子，C1-4烷基，C3-7环烷基，C3-7环烷基-C1-6烷基，COO（C1-6-烷基）基团，这些基团可选择地被替代；R5代表氢原子或C1-6烷基和n代表0到3及其在治疗由GSK3β异常活性引起的神经退行性疾病中的治疗用途。

  公开号：

  EP2090578A1
• 作为产物：
  描述：

  (+/-)-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-oxo-[1,4]diazepane-1-carboxylic acid ethyl ester 、 trimethoxonium tetrafluoroborate 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 12.0h， 以99%的产率得到(+/-)-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-methoxy-2,3,6,7-tetrahydro-[1,4]diazepine-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta

  摘要：

  公式（I）表示的嘧啶酮衍生物或其盐，或其溶剂或水合物：其中：Y代表两个氢原子，硫原子，氧原子或C1-2烷基和一个氢原子；Z代表键，氧原子，氮原子，被氢原子或C1-3烷基，硫原子，亚甲基基团替代的一个或两个基团，选自C1-6烷基，羟基，C1-6烷氧基，C1-2全氟烷基或氨基；R1代表2,3或4-吡啶环或2,4或5-嘧啶环，环可选择地被C1-6烷基，C1-6烷氧基或卤原子替代；R2代表氢原子，C1-6烷基或卤原子；R3代表苯环或萘环；环可选择地被替代R4代表氢原子，C1-4烷基，C3-7环烷基，C3-7环烷基-C1-6烷基，COO（C1-6-烷基）基团，这些基团可选择地被替代；R5代表氢原子或C1-6烷基和n代表0到3及其在治疗由GSK3β异常活性引起的神经退行性疾病中的治疗用途。

  公开号：

  EP2090578A1

文献信息

• Substituted arylamide diazepinopyrimidone derivatives
  申请人：Fayol Aude

  公开号：US08507476B2

  公开（公告）日：2013-08-13

  The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y, Z, R1, R2, R3, R4, R5 and n are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本公开涉及一系列由式（I）或其盐，溶剂或水合物表示的嘧啶酮衍生物：其中：Y，Z，R1，R2，R3，R4，R5和n如本公开所定义。还披露了制备式（I）化合物的方法，其中间体以及它们在治疗各种疾病状况方面的用途。
• SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES
  申请人：FAYOL Aude

  公开号：US20110039835A1

  公开（公告）日：2011-02-17

  The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y, Z, R1, R2, R3, R4, R5 and n are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本公开涉及一系列以式（I）表示的嘧啶酮衍生物或其盐、溶剂或水合物，其中：Y、Z、R1、R2、R3、R4、R5和n在本公开中定义。还公开了制备式（I）化合物的方法、其中间体及其在治疗多种疾病状况中的用途。
• SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA
  申请人：Sanofi-Aventis

  公开号：EP2238141A1

  公开（公告）日：2010-10-13
• [EN] SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA<br/>[FR] DÉRIVÉS D'ARYLAMIDE DIAZEPINOPYRIMIDONE SUBSTITUÉS POUR TRAITER LES MALADIES NEURODÉGÉNÉRATIVES DUES À UNE ACTIVITÉ ANORMALE DE GSK3-BÊTA
  申请人：SANOFI AVENTIS

  公开号：WO2009095789A1

  公开（公告）日：2009-08-06

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R3 represents a benzene ring or a naphthalene ring; the rings being optionally substituted R4 represents a hydrogen atom, a C1-6 alkyl group, a C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, a COO (C1-6-alkyl) group, these group being optionally substituted; R5 represents a hydrogen atom or a C1-6 alkyl group and n represents 0 to 3 and their therapeutic use for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3β.